

Diastereo- and enantioselective synthesis of a conagenin skeletal amide moiety

J. Augusto R. Rodrigues,* Paulo J. S. Moran, Cíntia D. F. Milagre and Cleber V. Ursini

Universidade Estadual de Campinas, Instituto de Química, CP 6154, 13084-971 Campinas SP, Brazil

Received 12 January 2004; revised 27 January 2004; accepted 10 March 2004

Abstract—A synthetic study was carried out to obtain epimers of a protected 2,4-dihydroxy-3-methylpentanoic ester **9**, which is a central building block of the immunomodulator (+)-conagenin **1**. The configuration of the three contiguous stereogenic centers was determined by NMR measurements and comparison with the stereogenic centers of lactone **10**.

© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

(+)-Conagenin **1** was isolated from fermentation broths of *Streptomyces roseosporus* by Ishizuka and co-workers after screening for substances that exhibit specific action on T cells by producing lymphokines as a low-molecular mass immunomodulator.¹ It was reported that **1** improved the antitumor efficacy of adriamycin and mitomycin C against murine leukemias, which suggest its potential utility for cancer chemotherapy.² The biological activity and the unique highly functionalized structure of (+)-conagenin has stimulated several efforts directed toward the synthesis of **1**. A first study was attempted by Sztaricskai and co-workers who obtained conagenin diastereoisomers using as starting material a functionalized D-xylose.³ The first total synthesis of (+)-conagenin was achieved by Irie et al. starting with the asymmetric aldol reaction of propiophenone with acetaldehyde followed by in situ *syn*-selective NaBH₄ reduction.⁴ A formal synthesis was achieved by Enders et al. in a 12-step sequence via asymmetric [2,3]-Wittig rearrangement of crotyloxyacetaldehyde-SAEP-hydrazone and the diastereoselective reduction of a methylketone.⁵ A second total synthesis by Sano et al., was accomplished based on enantioselective enzymatic reaction followed by chemoselective reduction.⁶ The combination of its biological activity and its unique structure of encouraged us to develop a new approach to




Figure 1. (+)-conagenin **1**.

the synthesis of amide moiety of conagenin **1** and its epimers (Fig. 1).

2. Results and discussion


Our strategy is based on the easy and inexpensive access to poly-[(*R*)-3-hydroxybutyric] acid (PHB)⁷ from the sugar cane industry, which is depolymerized to give ethyl (*R*)-(-)-3-hydroxybutanoate **2** after esterification of the corresponding acid in high yield and pure enantiomeric form (Scheme 1).⁸ Protection of the hydroxyl with TBDMSCl in the presence of imidazole/DMF gave **3** in high yield. Saponification with LiOH/H₂O in methanol and further acidification with HCl gave the corresponding acid **4** in 60% yield after two steps from **2**. Many methods are known for the conversion of carboxylic acids to 2-oxo esters.⁹ However, we required a strategy which would maintain the stereochemical integrity of the molecule and we favored a method involving ozonolysis of β-ketocyanophosphoranes, originally described by Wasserman and Ho.¹⁰ Treatment of the carboxylic acid **4** with (cyanomethylene)triphenylphosphorane in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) and 4-dimethylaminopyridine (DMAP) followed by ozonolysis of **5** in

Keywords: Conagenin; PHB-biopolymer; β-methylene-α-keto ester; Hydrogenation.

* Corresponding author. Tel.: +55-1937883141; fax: +55-1937883023; e-mail: jaugusto@iqm.unicamp.br

methanol and dichloromethane¹¹ gave the required 2-oxo ester (*R*)-(-)-**6** in 66% yield.¹²

It was then necessary to prepare the α -keto- β -methylene ester **7** that was obtained via direct Mannich methylation, using a methodology recently optimized in our laboratory,¹³ by heating (70 °C) a mixture containing the keto ester **6** in anhydrous acetic acid with a catalytic amount of morpholine and an excess of paraformaldehyde for 3 h. Compound **7** was obtained in 35% yield as a pale yellow oil.¹⁴ Efforts to improve the yield of **7** were unproductive. Hydrogenation of the α -keto- β -methylene ester **7** over 5% Pd/C were performed in ethyl acetate under atmospheric pressure to give *syn* and *anti* keto ester **8a/8b** in 70% yield in a ratio 93:7, respectively. Structural assignments of the isomers were determined by ¹H and ¹³C NMR spectroscopy. The magnitudes of the 3-H and 4-H vicinal coupling constants of *syn* (5.1 Hz) and *anti* (7.5 Hz) isomers are consistent with those observed for β -hydroxy (or β -silyloxy)- α -methyl esters,¹⁵ thioesters,^{15a} aldehydes,¹⁶ acids,¹⁷ amides,¹⁸ and ketones.¹⁹ The ¹³C NMR resonances of 3-C, 4-C and methyl-3-C of *syn* isomer **8a** appeared at higher fields than the respective carbons of *anti* **8b**. This behavior is in accordance with empirical observations that allow the assignment of the stereostructure of β -hydroxycarbonyl compounds possessing diastereoisomerism.²⁰ Similar β -silyloxy carbonyl compounds show the same pattern for ¹³C NMR spectra.^{21,15f} The stereochemical outcome of this hydrogenation can be rationalized on the basis of the Felkin²² and the Cram²³ models. The α -ketoesters mixture **8a** and **8b** was reduced with tetrabutylammonium borohydride in methanol at -78 °C to give a diastereomeric mixture of α -hydroxyesters **9a–c** in 67% yield, having a ratio of 85:6:9, respectively (Scheme 2).



Scheme 1. Reagents and conditions: (a) 1,2-dichloroethane, EtOH, cat. H₂SO₄, two days (60% yield); (b) TBDMSCl, imidazole, DMF; (c) LiOH, MeOH, H₂O/HCl (60% yield, two steps); (e) Ph₃PCHCN, EDCl, DMAP, CH₂Cl₂; (e) O₃, MeOH, CH₂Cl₂, -78 °C (66% yield, two steps); (f) (CH₂O)_n, morpholine, HOAc, 70 °C (35% yield); (g) H₂, Pd–C 5%, EtOAc (70% yield, **8a:8b** 93:7).





Figure 2. Selected ¹H–¹H NOE enhancements (500 MHz, ¹H NMR, CDCl₃) for **10a**.

Purification by silica gel flash chromatography eluted with hexane (95%):ethyl acetate isolated pure **9a**²⁴ in 53% yield and **9c:9b**²⁵ in a 9/1 ratio, as determined by NMR. Considering that **9c** has the correct *syn* stereochemistry for the three contiguous chiral centers of the amide moiety of conagenin **1**, we decided to search for other reagents to reduce **8a/8b** to improve its amount in the product ratio. Reduction with LiBH₄ in ethyl ether at -90 °C increased the quantity of **9c** to 41% (Scheme 2). Deprotection of **9a** with tetrabutylammonium fluoride in THF gave the lactone **10a**²⁶ in 70% yield. The ¹H NMR of **10a** shows coupling constants $J_{3,4} = 7.3$ Hz and $J_{4,5} = 4.6$ Hz that are in agreement with previous coupling constant analyses and conformational studies by MM2 calculations of substituted γ -lactones with vicinal hydrogen atoms.²⁷ The stereochemistry of **10a** was also revealed by NOE analysis (500 MHz, CDCl₃, Fig. 2). Under the same conditions, **9c** was deprotected and cyclized to lactone **10c** in high yield. The ¹H NMR coupling constant of **9c** for the vicinal $J_{2,3}$ (2.4 Hz) and $J_{3,4}$ (5.8 Hz) are close to those for (+)-conagenin **1**.⁶ Lactone **10c**²⁸ shows $J_{3,4} = 10.3$ Hz and $J_{4,5} = 7.0$ Hz, also in agreement with the calculated coupling constants: $J_{3,4} = 9.8$ Hz and $J_{4,5} = 7.1$ Hz.²⁷ The magnitude of $J_{3,4}$ (10.3 Hz) is characteristic for hydrogens 3-H and 4-H with *trans* geometry.^{16,27}

In conclusion, we have developed a new short route for the synthesis of the amide moiety of conagenin and its epimers. The β -methylene- α -keto ester **7** proved its versatility for obtaining the conagenin skeleton through hydrogenation reduction of the enone moiety with asymmetric induction. The ¹H NMR coupling constants and formation of the lactones allow characterization of all the isolated diastereoisomers.

Acknowledgements

We thank FAPESP for financial support and for a scholarship for C.V.U., and Dr. Gilson H. M. Dias for the use of his lab facilities.



Scheme 2. Reagents and conditions: (1) Bu₄NBH₄, MeOH, -78 °C (67% yield, **9a:b:c** 85:6:9); (2) LiBH₄, Et₂O, -90 °C (53% yield, **9a:b:c** 54:5:41).

References and notes

- (a) Yamashita, T.; Iijima, M.; Nakamura, H.; Isshiki, K.; Naganawa, H.; Hattori, S.; Hamada, M.; Ishizuka, M.; Takeuchi, T. *J. Antibiot.* **1991**, *44*, 557–559; (b) Kawatsu, M.; Yamashita, T.; Osono, M.; Ishizuka, M.; Takeuchi, T. *J. Antibiot.* **1993**, *46*, 1687–1691; (c) Ishizzuka, M.; Kawatsu, M.; Yamashita, T.; Ueno, M.; Takeuchi, T. *Int. J. Immunopharmacol.* **1995**, *17*, 133–139.
- (a) Kawatsu, M.; Yamashita, T.; Ishizuka, M.; Takeuchi, T. *J. Antibiot.* **1995**, *48*, 222–225; (b) Hamada, M.; Yamamoto, S.; Moriguchi, S.; Kishino, Y. *J. Antibiot.* **2001**, *54*, 349–353; (c) Hamada, M.; Sonotake, E.; Yamamoto, S. Moriguchi, S. *J. Antibiot.* **1999**, *52*, 548–551.
- Kovács-Kulyassa, Á.; Herczegh, P.; Sztaricskai, F. J. *Tetrahedron Lett.* **1996**, *37*, 2499–2502.
- Hatakeyama, S.; Fukuyama, H.; Mukugi, Y.; Irie, H. *Tetrahedron Lett.* **1996**, *37*, 4047–4050.
- Enders, D.; Bartsch, M.; Runsink, J. *Synthesis* **1999**, 243–248.
- Sano, S.; Miwa, T.; Hayashi, K.; Nozaki, K.; Ozaki, Y.; Nagao, Y. *Tetrahedron Lett.* **2001**, *42*, 4029–4031.
- Bachmann, B. M.; Seebach, D. *Helv. Chim. Acta* **1998**, *81*, 2430–2461.
- Seebach, D.; Beck, A. K.; Breitschuh, R.; Job K. *Org. Synth.* **1993**, *71*, 39–47.
- For reviews of the synthesis of 2-oxo esters see: (a) Kovacs, L. *Recl. Trav. Chim. Pays-Bas* **1993**, *112*, 471–496; (b) Copper, A. J. L.; Ginos, J. Z.; Meister, A. *Chem. Rev.* **1983**, *83*, 321–358.
- Wasserman, H. H.; Ho, W.-B. *J. Org. Chem.* **1994**, *59*, 4364–4366.
- This methodology was also employed by Bhalay, G.; Clough, S.; McLaren, L.; Sutherland, A.; Willis, C. L. *J. Chem. Soc., Perkin Trans. 1* **2000**, 901–910.
- (R)-**6**: $[\alpha]_D^{20} - 22.4$ (c 1.21 CHCl₃); IR (thin film) ν (C=O) 1755, 1733 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ_H 4.38 (m, 1H, 4-H), 3.85 (s, 3H, CO₂CH₃), 3.04 (dd, 1H, $J_{3,3} = 15.6$, $J_{3,4} = 7.3$, 3-HH), 2.87 (dd, 1H, $J_{3,3} = 15.6$, $J_{3,4} = 5.2$, 3-HH), 1.21 (d, 3H, $J_{4,5} = 6.1$, 5-H₃), 0.84 [s, 9H, Si(CH₃)₃], 0.053 (s, 3H, SiCH₃), 0.017 (s, 3H, SiCH₃).
- Rodrigues, J. A. R.; Siqueira-Filho, E. P.; de Mancelha, M.; Moran, P. J. S. *Synth. Commun.* **2003**, *33*, 331–340.
- (R)-**7**: $[\alpha]_D^{20} - 27.6$ (c 1.66, CHCl₃); IR (thin film) ν (C=O) 1746, 1682 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ_H 6.54 (d, 1H, $J = 1.1$ Hz, =CHH), 6.24 (s, 1H, =CHH), 4.76 (q, 1H, $J_{4,5} = 6.2$ Hz, 4-H), 3.91 (s, 3H, CO₂CH₃), 1.28 (d, 3H, $J_{4,5} = 6.2$ Hz, 5-H₃), 0.91 [s, 9H, Si(CH₃)₃], 0.084 (s, 3H, SiCH₃), 0.039 (s, 3H, SiCH₃). Anal. Calcd for C₁₃H₂₄O₄Si: C, 57.32; H, 8.88. Found: C, 57.07; H, 9.0.
- (a) Evans, D. A.; Kozlowski, M. C.; Murry, J. A.; Burgey, C. S.; Campos, K. R.; Connell, B. T.; Staples, R. J. *J. Am. Chem. Soc.* **1989**, *111*, 669–685; (b) Slough, G. A.; Bergman, R. G.; Heathcock, C. H. *J. Am. Chem. Soc.* **1999**, *121*, 938–949; (c) Hoffmann, R. W.; Dresely, S.; Lanz, J. W. *Chem. Ber.* **1988**, *121*, 1501–1507; (d) Fráter, G.; Müller, U.; Günther, W. *Tetrahedron* **1984**, *40*, 1269–1277; (e) Scheidt, K. A.; Bannister, T. D.; Tasaka, A.; Wendt, M. D.; Savall, B. M.; Fegley, G. J.; Roush, W. R. *J. Am. Chem. Soc.* **2002**, *124*, 6981–6990; (f) Mateus, C. R.; Feltrin, M. P.; Costa, A. M.; Coelho, F.; Almeida, W. P. *Tetrahedron* **2001**, *57*, 6901–6908; (g) Keck, G. E.; Kachensky, D. F.; Enholm, E. J. *J. Org. Chem.* **1985**, *50*, 4317–4325.
- Barrett, A. G. M.; Lebold, S. A. *J. Org. Chem.* **1991**, *56*, 4875–4884.
- Renauld, P.; Seebach, D. *Helv. Chim. Acta* **1986**, *69*, 1704–1710.
- Evans, D. A.; Ratz, A. M.; Huff, B. E.; Sheppard, G. S. *J. Am. Chem. Soc.* **1995**, *117*, 3448–3467.
- Enders, D.; Bartsch, M.; Runsink, J. *Synthesis* **1999**, 243–248.
- Heathcock, C. H.; Pirrung, M. C.; Sohn, J. E. *J. Org. Chem.* **1979**, *44*, 4294–4299.
- Hoffmann, R. W.; Weidmann, U. *Chem. Ber.* **1985**, *118*, 3966–3979.
- Jackson, R. F. W.; Standen, S. P.; Clegg, W.; McCamley, A. *Tetrahedron Lett.* **1992**, *33*, 6197–6200.
- Augustine, R. L. *Catal. Today* **1997**, *37*, 419–440.
- Methyl (2*S*,3*S*,4*R*)-4-(*t*-butyldimethylsilyloxy)-2-hydroxy-3-methylpentanoate **9a**: IR (thin film) 3476 (br) and 1738 cm⁻¹; $[\alpha]_D^{23} - 4.0$ (c 1.03, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ_H 4.16 (dd, 1H, $J_{2,3} = 7.0$ Hz, $J_{2,2-OH} = 6.4$ Hz, 2-H), 4.09 (dq, 1H, $J_{4,5} = 6.4$ Hz, $J_{3,4} = 3.0$ Hz, 4-H), 3.88 (d, 1H, $J_{2,2-OH} = 6.1$ Hz, OH), 3.77 (s, 3H, CO₂CH₃), 1.92 (dq, 1H, $J_{3,3-methyl} = 7.0$ Hz, $J_{2,3} = 7.0$ Hz, $J_{3,4} = 3.0$ Hz, 3-H), 1.18 (d, 3H, $J_{4,5} = 6.4$ Hz, 5-H₃), 0.93 (d, 3H, $J_{3,3-methyl} = 7.0$ Hz 3-C-CH₃), 0.90 [s, 9H, Si(CH₃)₃], 0.11 (s, 3H, SiCH₃), 0.09 (s, 3H, SiCH₃); ¹³C (1H) NMR, (125.7 MHz, CDCl₃) δ_C 174.59 (1-C), 74.73 (2-C or 4-C), 70.42 (4-C or 2-C), 51.92 (O-CH₃), 42.74 (3-C), 25.78 [Si(CH₃)₃], 19.99 (SiC), 17.93 (SiC), 11.22 (3-CCH₃), -4.24 (SiCH₃), -5.03 (SiCH₃). Anal. Calcd for C₁₃H₂₈O₄Si (276.44): C, 56.48; H, 10.21. Found: C, 56.44; H, 10.47.
- 9c/9b**: 9:1 ratio, IR (thin film): ν (OH) 3500 (br s), ν (C=O) 1738 cm⁻¹ (s) $[\alpha]_D^{23} - 70$ (c 0.22, CHCl₃) Methyl (2*R*,3*S*,4*R*)-4-(*tert*-butyldimethylsilyloxy)-2-hydroxy-3-methylpentanoate **9c**: ¹H NMR (500 MHz, CDCl₃) δ_H 4.45 (dd, 1H, $J_{2,3} = 2.4$ Hz, $J_{2,2-OH} = 4.3$ Hz, 2-H) 3.93 (apparent quint, 1H, $J_{4,5} = 6.1$ Hz, $J_{3,4} = 5.8$ Hz, 4-H), 3.79 (s, 3H, CO₂CH₃), 3.05 (d, 1H, $J_{2,2-OH} = 4.3$ Hz, OH), 1.95 (ddq, 1H, $J_{3,3-methyl} = 7.0$ Hz, $J_{2,3} = 2.4$ Hz, $J_{3,4} = 5.8$ Hz, 3-H), 1.22 (d, 3H, $J_{4,5} = 6.1$ Hz, 5-H₃), 0.90 [s, 9H, Si(CH₃)₃], 0.88 (d, 3H, $J_{3,3-methyl} = 7.0$ Hz, 3-C-CH₃), 0.087 (s, 3H, SiCH₃), 0.081 (s, 3H, SiCH₃); ¹³C {¹H} NMR. (125.7 MHz, CDCl₃) δ_C 175.27 (1-C), 72.29 (2-C or 4-C), 71.26 (4-C or 2-C), 52.45 (O-CH₃), 43.44 (3-C), 25.81 [Si(CH₃)₃], 21.06 (5-C), 17.98 (SiC), 8.94 (3-CCH₃), -4.11 (Si-CH₃), -4.90 (Si-CH₃). Methyl (2*R*,3*R*,4*R*)-4-(*tert*-butyldimethylsilyloxy)-2-hydroxy-3-methylpentanoate **9b**: ¹H NMR δ_H (500 MHz, CDCl₃): 4.21 (dd, 1H, $J_{2,3} = 4.3$ Hz, $J_{2,2-OH} = 5.5$ Hz, 2-H) 3.89 (apparent quint, 1H, $J = 6.4$ Hz, 4-H), 3.78 (s, 3H, CO₂CH₃), 3.37 (d, 1H, $J_{2,2-OH} = 5.9$ Hz, OH), 2.00 (m, 1H, $J = 7.0$ Hz, $J = 4.6$ Hz, 3-H), 1.16 (d, 3H, $J_{4,5} = 6.1$ Hz, 5-H₃), 0.97 (d, 3H, $J_{3,3-methyl} = 7.0$ Hz, 3-C-CH₃), 0.89 [s, 9H, Si(CH₃)₃], 0.077 (s, 3H, SiCH₃), 0.071 (s, 3H, SiCH₃); ¹³C {¹H} NMR. δ_C (125.7 MHz, CDCl₃): 175.04 (1-C), 73.57 (2-C or 4-C), 70.84 (4-C or 2-C), 52.08 (O-CH₃), 44.31 (3-C), 25.86 [Si(CH₃)₃], 21.55 (5-C), 17.98 (SiC), 13.52 (3-CCH₃), -4.34 (Si-CH₃), -4.73 (Si-CH₃).
- (3*S*,4*S*,5*R*)-3-hydroxy-4,5-dimethyl-tetrahydrofuran-2-one **10a**: $[\alpha]_D^{23} + 17$ (c 0.080, CHCl₃); IR (nujol): ν (OH) 3440 cm⁻¹ (br, s), ν (C=O) 1766 cm⁻¹ (s); ¹H NMR δ_H (500 MHz, CDCl₃): 4.58 (dq, 1H, $J_{4,5} = 4.6$ Hz, $J_{5,5-methyl} = 6.4$ Hz, 5-H), 4.57 (d, 1H, $J_{3,4} = 7.3$ Hz, 3-H), 2.70 (apparent dq and br s, 2H, $J = 7.3$ Hz, $J_{4,5} = 4.6$ Hz, 4-H and -OH), 1.38 (d, 3H, $J_{5,5-methyl} = 6.4$ Hz, 5-CH₃), 0.95 (d, 3H, $J_{4,4-methyl} = 7.3$ Hz, 4-CH₃); ¹³C {¹H} NMR. δ_C (125.7 MHz, CDCl₃): 177.32 (2-C), 76.20 (3-C or 5-C), 71.80 (5-C or 3-C), 39.24 (4-C), 15.45 (5-CCH₃), 6.37 (4-CCH₃).
- Jaime, C.; Segura, C.; Dinarés, I.; Font, J. *J. Org. Chem.* **1993**, *58*, 154–158.
- (3*R*,4*S*,5*R*)-3-hydroxy-4,5-dimethyl-tetrahydrofuran-2-one **10c**: mp 69–72 °C; $[\alpha]_D^{23} + 60$ (c 0.027, CHCl₃); IR

(nujol): ν (OH) 3400 cm^{-1} (br, s), ν (C=O) 1760 cm^{-1} (s);
 $^1\text{H NMR } \delta_{\text{H}}$ (300 MHz, CDCl_3): 4.72 (quint, 1H,
 $J_{4,5} = 7.0\text{ Hz}$, $J_{5,5\text{-methyl}} = 7.0\text{ Hz}$, 5-H), 4.11 (d, 1H, $J_{3,4} =$

10.3 Hz, 3-H), 2.58 (m, 2H, 4-H and -OH), 1.31 (d, 3H,
 $J_{5,5\text{-methyl}} = 6.6\text{ Hz}$, 5- CH_3), 1.21 (d, 3H, $J_{4,4\text{-methyl}} = 6.9\text{ Hz}$,
4- CH_3).